MX2009005622A - Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores. - Google Patents

Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.

Info

Publication number
MX2009005622A
MX2009005622A MX2009005622A MX2009005622A MX2009005622A MX 2009005622 A MX2009005622 A MX 2009005622A MX 2009005622 A MX2009005622 A MX 2009005622A MX 2009005622 A MX2009005622 A MX 2009005622A MX 2009005622 A MX2009005622 A MX 2009005622A
Authority
MX
Mexico
Prior art keywords
treatment
compounds
dihydroimidazoles
peptide
interaction
Prior art date
Application number
MX2009005622A
Other languages
English (en)
Inventor
Juerg Zimmermann
Sylvie Chamoin
Thomas Zoller
Hans-Joerg Roth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009005622A publication Critical patent/MX2009005622A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/40—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a dihidro-imidazoles de la fórmula rac-(I): (ver fórmula (I)) en donde los radicales y símbolos son como se definen en la presente; a su uso como inhibidores de la interacción de la proteína MDM2 con un péptido tipo p53, a nuevas formulaciones farmacéuticas que comprenden estos compuestos, a estos compuestos para utilizarse en el tratamiento terapéutico de animales de sangre caliente, en especial de seres humanos, a su uso en le tratamiento de enfermedades proliferativas o para la fabricación de formulaciones farmacéuticas útiles en el tratamiento de enfermedades proliferativas que respondan a la modulación de la interacción de la proteína MDM2 con un péptido tipo p53, a una formulación farmacéutica, pro ejemplo, útil en el tratamiento de enfermedades proliferativas que respondan a la modulación de la interacción de la proteína MDM2 con un péptido tipo p53 que comprenda dicho compuesto, a métodos de tratamiento que comprenden la administración de tales compuestos a un animal de sangre caliente, y/o a procesos para la fabricación de estos compuestos.
MX2009005622A 2006-11-27 2007-11-26 Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores. MX2009005622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124802 2006-11-27
PCT/EP2007/062804 WO2008065068A2 (en) 2006-11-27 2007-11-26 Substituted dihydroimidazoles and their use in the treatment of tumors

Publications (1)

Publication Number Publication Date
MX2009005622A true MX2009005622A (es) 2009-06-12

Family

ID=38288488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005622A MX2009005622A (es) 2006-11-27 2007-11-26 Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.

Country Status (10)

Country Link
US (1) US20100075966A1 (es)
EP (1) EP2097386A2 (es)
JP (1) JP2010510974A (es)
KR (1) KR20090083408A (es)
CN (1) CN101541759A (es)
AU (1) AU2007327621A1 (es)
BR (1) BRPI0719345A2 (es)
CA (1) CA2670105A1 (es)
MX (1) MX2009005622A (es)
WO (1) WO2008065068A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696174A1 (en) 2005-11-08 2020-08-19 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
CN101687842B (zh) 2007-05-09 2013-03-06 沃泰克斯药物股份有限公司 Cftr调节剂
LT2639223T (lt) 2007-12-07 2017-06-26 Vertex Pharmaceuticals Incorporated Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas
CN103626744B (zh) 2007-12-07 2016-05-11 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
ES2552990T3 (es) * 2008-03-31 2015-12-03 Vertex Pharmaceuticals Incorporated Derivados de piridilo como moduladores del CFTR
ES2700613T3 (es) * 2008-07-16 2019-02-18 Bitop Ag Síntesis de amidinas cíclicas
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP2621275B1 (en) 2010-09-30 2018-03-28 St. Jude Children's Research Hospital Aryl-substituted imidazoles
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
CN107110831B (zh) 2014-11-18 2020-02-21 弗特克斯药品有限公司 进行高通量试验高效液相色谱的方法
JP6848055B2 (ja) * 2017-06-16 2021-03-24 ユニティ バイオテクノロジー インコーポレイテッド 薬学的使用のための鏡像異性的に純粋なシス‐イミダゾリン化合物を生成するための合成方法
EP4069691A1 (en) 2019-12-06 2022-10-12 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
KR102622992B1 (ko) * 2021-03-29 2024-01-10 주식회사 퓨전바이오텍 이미다졸린 유도체 및 이의 중간체 제조방법
AU2022284886A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11976047B1 (en) * 2023-11-07 2024-05-07 King Faisal University 4,5-bis(4-bromo-phenyl)-1-hexyl-2-(2- methoxyphenyl)-1H-imidazole as an antimicrobial compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005011132D1 (de) * 2004-05-18 2009-01-02 Hoffmann La Roche Neuartige cis-imidazoline

Also Published As

Publication number Publication date
WO2008065068A3 (en) 2008-07-24
EP2097386A2 (en) 2009-09-09
BRPI0719345A2 (pt) 2014-03-18
CN101541759A (zh) 2009-09-23
CA2670105A1 (en) 2008-06-05
JP2010510974A (ja) 2010-04-08
WO2008065068A2 (en) 2008-06-05
AU2007327621A1 (en) 2008-06-05
US20100075966A1 (en) 2010-03-25
KR20090083408A (ko) 2009-08-03

Similar Documents

Publication Publication Date Title
MX2009005622A (es) Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
MEP3808A (xx) Derivati pirimidinil aril uree kao fgf inhibitori
HK1131608A1 (en) Pyridinone compounds
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA201100032A1 (ru) Соединения пиридина
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
GB0606805D0 (en) Organic compounds
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2010010505A (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
TW200612922A (en) Inhibitors of hsp90
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA201101579A1 (ru) Имидазо[1,2-а]пиридин-2-ил-фенил производные для лечения рака
EA201071307A1 (ru) Карбамоильные производные бициклических карбониламинопиразолов в качестве пролекарств
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
WO2006138589A3 (en) Opioid receptor ligands

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal